Cantor Fitzgerald Keeps a Buy Rating on Aridis Pharmaceuticals Inc (ARDS)


Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Aridis Pharmaceuticals Inc (ARDS) yesterday and set a price target of $25. The company’s shares closed yesterday at $10.56.

Chen observed:

“. Post a solid quarter of execution in 4Q18, we reiterate our OW rating and 12-month price target of $25 for ARDS shares. We continue to believe that upward earnings revisions and multiple expansion will drive the stock higher. We think a greater appreciation for the company’s pipeline drugs will increase earnings estimates to levels not yet reflected in consensus expectations.”

According to TipRanks.com, Chen is a 5-star analyst with an average return of 11.8% and a 44.5% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Amneal Pharmaceuticals Inc, and Melinta Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aridis Pharmaceuticals Inc with a $25 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $13.85 and a one-year low of $7.59. Currently, Aridis Pharmaceuticals Inc has an average volume of 4,590.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-105, AR-101, AR-401, AR-201, and AR-501. The company was founded by Eric J. Patzer and Vu L. Truong in 2003 and is headquartered in San Jose, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts